Many specialty pharmaceutical stocks have been hit hard recently on fears surrounding the potential for major reforms in drug pricing regulation. However, according to Leerink analyst Jason Gerberry, the majority of investor fears are unwarranted.

Leerink recently hosted a conference call with two MEDACorp payer specialists and spoke with a health law attorney about the real risks that Hillary Clinton’s plan or a similar plan on drug pricing could pose for pharma stocks.

Congressional Roadblock

According to Gerberry, the consensus among industry experts is that the Republican-controlled Congress will not allow any meaningful drug pricing reforms at least through 2017. In addition, attorneys have told Leerink that the drug re-importation aspect of Clinton’s plan has “near zero odds” of being passed into law.

Most Realistic Proposed Changes

Gerberry sees…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!